Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.35 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3799554 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL276295 | 0.71 | CYP2A6 (0.55) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL1866237 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL14022908 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL389275 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL156699 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL911242 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL594318 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL2011067 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL288299 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111057074-B | Inhibitors of influenza virus replication and uses thereof | 广东东阳光药业有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-111057074-A | Inhibitors of influenza virus replication and uses thereof | 广东东阳光药业有限公司 | 2020-04-24 | — | — | CN | disclosed |
| US-7037932-B2 | Heteroaryloxy 3-substituted propanamines as serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1397129-B1 | HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040176435-A1 | Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY | 2004-09-09 | — | — | US | disclosed |
| EP-1397129-A1 | HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094262-A1 | HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
| US-5730860-A | USING ABSORBENT; COUNTERCURRENT FLOW | THE PRITCHARD CORPORATION (US) | 1998-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176435-A1 | Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors | ADRA2C, ADRB1, TPH1 | CYP2A6 178/4885HDAC4 1135/4885PSMD14 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.